August 2024

On the road

Haematex is proud to introduce Melissa Pomfret as our new business development manager.

Melissa previously worked for IL/Werfen, BioRad and Siemens. Most recently successfully promoting acute care products such as Rotem, Haemochron and GEM blood gas devices. She is now looking to help clotters find solutions through the Hyphen Biomed range of reagents.

You can meet Melissa at the THANZ workshop in Brisbane on Saturday 26th October, contact her at melissa@haematex.com to arrange a meeting to discuss products and solutions. Welcome Melissa!

‍

Did you know?

Hyphen BioMed (HBM) could be described as the smaller/second French company specializing in blood coagulation. HBM was set up by Dr Jean Amiral, probably best known for identifying the heparin/platelet factor 4 as the antigen involved in HITTS (heparin induced thrombotic thrombocytopenic syndrome) while at Diagnostica Stago.

Jean departed from Stago some 20 years ago and set up HBM to carry out more interesting research work and to develop more convenient research kits for clinical trials and the diagnostic industry. These kits include the best heparin test methods and clotting and chromogenic methods for DOACs.

The range of ELISAs available includes esoteric analytes such as annexin V, thrombin activatable fibrinolysis inhibitor (TAFI), platelet factor 4, free protein S, protein Z among others.

‍

What’s New?

Complementary to application guides, Hyphen have now released XML files to be installed on Sysmex CS/CN series. With the EU moving to the new regulatory framework IVDR, application guides and XML files for their product range will be rolled over the next few months and they strongly recommend installing the programs. Please contact us at htx@haematex.com to see if your relevant files are currently available.

‍

Haematex is the only Australian distributor which carries out local R&D into coagulation diagnostics. When you purchase from us, a portion of profits go towards projects such as our own locally made DOAC-Stop™, and research on dRVVT and lupus anticoagulants. We hope this newsletter has been of interest, if you do not wish to receive future updates, please let us know.

‍